Equillium to Participate in the 38th Annual Roth Conference
LA JOLLA, Calif., March 18, 2026 -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38
Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.
About Equillium
Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. EQ504 is an investigational therapeutic program with potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Is NEAR Protocol’s 60% Rally Just Getting Started?
Is BSB Price Preparing For A Push Toward $2?
BEAT Price Explodes 170% As Audiera Retail Frenzy Builds
Altcoin Rotation Builds as BTC Dominance Weakens
Trending news
MoreCrypto prices
More
